PT  - JOURNAL ARTICLE
AU  - Robert Moss
AU  - David J. Price
AU  - Nick Golding
AU  - Peter Dawson
AU  - Jodie McVernon
AU  - Rob J. Hyndman
AU  - Freya M. Shearer
AU  - James M. McCaw
TI  - Forecasting COVID-19 activity in Australia to support pandemic response: May to October 2020
AID  - 10.1101/2022.08.04.22278391
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.04.22278391
4099  - http://medrxiv.org/content/early/2022/08/06/2022.08.04.22278391.short
4100  - http://medrxiv.org/content/early/2022/08/06/2022.08.04.22278391.full
AB  - As of January 2021, Australia had effectively controlled local transmission of COVID-19 despite a steady influx of imported cases and several local, but contained, outbreaks in 2020. Throughout 2020, state and territory public health responses were informed by weekly situational reports that included an ensemble forecast for each jurisdiction. We present here an analysis of one forecasting model included in this ensemble across the variety of scenarios experienced by each jurisdiction from May to October 2020. We examine how successfully the forecasts characterised future case incidence, subject to variations in data timeliness and completeness, showcase how we adapted these forecasts to support decisions of public health priority in rapidly-evolving situations, evaluate the impact of key model features on forecast skill, and demonstrate how to assess forecast skill in real-time before the ground truth is known. Conditioning the model on the most recent, but incomplete, data improved the forecast skill, emphasising the importance of developing strong quantitative models of surveillance system characteristics, such as ascertainment delay distributions. Forecast skill was highest when there were at least 10 reported cases per day, the circumstances in which authorities were most in need of forecasts to aid in planning and response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was directly funded by the Australian Government Department of Health. Additional support was provided by the National Health and Medical Research Council of Australia through its Centres of Research Excellence (SPECTRUM, GNT1170960) and Investigator Grant Schemes (JMcV Principal Research Fellowship, GNT1117140).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was undertaken as urgent public health action to support Australia's COVID-19 pandemic response. The study used data from the Australian National Notifiable Disease Surveillance System (NNDSS) provided to the Australian Government Department of Health and Aged Care under the National Health Security Agreement for the purposes of national communicable disease surveillance. Data from the NNDSS were supplied after de-identification to the investigator team for the purposes of provision of epidemiological advice to government. Contractual obligations established strict data protection protocols agreed between the University of Melbourne and sub-contractors and the Australian Government Department of Health and Aged Care, with oversight and approval for use in supporting Australia's pandemic response and for publication provided by the data custodians represented by the Communicable Diseases Network of Australia. The ethics of the use of these data for these purposes, including publication, was agreed by the Department of Health and Aged Care with the Communicable Diseases Network of Australia.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the simulation code and forecast outputs used to generate the results in this manuscript and the supplementary materials are provided in a public repository (https://gitlab.unimelb.edu.au/rgmoss/aus-2020-covid-forecasts). The input data are provided in a separate dataset (doi:10.26188/19315055). https://gitlab.unimelb.edu.au/rgmoss/aus-2020-covid-forecasts https://doi.org/10.26188/19315055